NASH is associated with increased risk of mortality. Currently, there are few treatment options. Therefore, there is a need for an effective and safe medication treatment options. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), can address certain aspects of NASH and is therefore considered a strong candidate for the treatment of NASH.

If you enroll in this study, you will undergo a series of testing. You will be asked to complete an initial assessment that includes a physical exam, vital signs, waist circumference, height, and weight measurements, questionnaires, COVID-19 screening and test, a liver biopsy, blood draws, eye examination, and pregnancy test, if applicable. You will be randomized to either Semaglutide 2.4 mg once weekly or placebo (an inactive substance of no medical value). For treatment, you will be asked to inject yourself once a week for with the study medicine. You will be asked to come in for 21 study visits to evaluate your health and the effect of the study medicine at week 0, week 2, week 8, week 12, week 16, week 24, week 36, week 48, week 60, week 72, week 78, week 96, week 108, week 120, week 144, week 156, week 168, week 192, week 204, week 216, week 240 and week 247. There will be up to 9 phone calls with the study staff.

1,050.00